Paper40682115
SNRPB/CCNB1 axis promotes hepatocellular carcinoma progression and cisplatin resistance through enhancing lipid metabolism reprogramming.
Jin X and 12 others. J Exp Clin Cancer Res, 2025. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. SNRPB/CCNB1 axis promotes hepatocellular carcinoma progression and cisplatin resistance through enhancing lipid metabolism reprogramming. Papers, record 40682115. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40682115
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- SNRPB/CCNB1 axis promotes hepatocellular carcinoma progression and cisplatin resistance through enhancing lipid metabolism reprogramming.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Cisplatin | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Lipid Metabolism | Major topic |
| Cyclin B1 | Major topic |
| Humans | |
| Animals | |
| Mice | |
| Disease Progression | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Forkhead Box Protein M1 | |
| Gene Expression Regulation, Neoplastic | |
| Male | |
| Metabolic Reprogramming |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2022YFE0125300 | National Key Research and Development Plan of the Ministry of Science and Technology | PubMed | ||
| 22ZR1413300 | Shanghai Natural Science Foundation Project | PubMed | ||
| 202240240 | the Public Health Bureau Foundation of Shanghai | PubMed |
Source PubMed
References58
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20661013 | Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. | Am J Surg Pathol | 2010 | https://conductscience.org/library/papers/20661013 | PubMed |
| 2 | 36878933 | CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. | Cell Discov | 2023 | https://conductscience.org/library/papers/36878933 | PubMed |
| 3 | 33281098 | Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance. | Trends Cancer | 2021 | https://conductscience.org/library/papers/33281098 | PubMed |
| 4 | 33824478 | α-Fetoprotein mRNA in situ hybridisation is a highly specific marker of hepatocellular carcinoma: a multi-centre study. | Br J Cancer | 2021 | https://conductscience.org/library/papers/33824478 | PubMed |
| 5 | 37758792 | A pancancer analysis of the oncogenic role of cyclin B1 (CCNB1) in human tumors. | Sci Rep | 2023 | https://conductscience.org/library/papers/37758792 | PubMed |
| 6 | 32332754 | Accurate estimation of cell composition in bulk expression through robust integration of single-cell information. | Nat Commun | 2020 | https://conductscience.org/library/papers/32332754 | PubMed |
| 7 | 35262876 | CCNB1, Negatively Regulated by miR-559, Promotes the Proliferation, Migration, and Invasion of Ovarian Carcinoma Cells. | Mol Biotechnol | 2022 | https://conductscience.org/library/papers/35262876 | PubMed |
| 8 | 35229723 | SIRPγ-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling. | J Clin Invest | 2022 | https://conductscience.org/library/papers/35229723 | PubMed |
| 9 | 32106364 | SNRPB promotes cervical cancer progression through repressing p53 expression. | Biomed Pharmacother | 2020 | https://conductscience.org/library/papers/32106364 | PubMed |
| 10 | 28514441 | PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. | Nature | 2017 | https://conductscience.org/library/papers/28514441 | PubMed |
| 11 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 12 | 36400469 | Hepatocellular Carcinoma: New Developments. | Clin Liver Dis | 2023 | https://conductscience.org/library/papers/36400469 | PubMed |
| 13 | 32372477 | Highly upregulated in liver cancer (HULC): An update on its role in carcinogenesis. | J Cell Physiol | 2020 | https://conductscience.org/library/papers/32372477 | PubMed |
| 14 | 37584444 | Defects of the spliceosomal gene SNRPB affect osteo- and chondro-differentiation. | FEBS J | 2024 | https://conductscience.org/library/papers/37584444 | PubMed |
| 15 | 36192773 | ACSL3 regulates lipid droplet biogenesis and ferroptosis sensitivity in clear cell renal cell carcinoma. | Cancer Metab | 2022 | https://conductscience.org/library/papers/36192773 | PubMed |
| 16 | 29420223 | Oxidative Phosphorylation as an Emerging Target in Cancer Therapy. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29420223 | PubMed |
| 17 | 38772352 | Hepatocellular Carcinoma: Prevention, Diagnosis, and Treatment. | Med Princ Pract | 2024 | https://conductscience.org/library/papers/38772352 | PubMed |
| 18 | 29784041 | Lipid metabolism reprogramming and its potential targets in cancer. | Cancer Commun (Lond) | 2018 | https://conductscience.org/library/papers/29784041 | PubMed |
| 19 | 36601001 | CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine. | Front Endocrinol (Lausanne) | 2022 | https://conductscience.org/library/papers/36601001 | PubMed |
| 20 | 36924123 | Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences. | Clin Mol Hepatol | 2023 | https://conductscience.org/library/papers/36924123 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42919977 | Rosmarinic acid combined with cisplatin induces proliferation inhibition of hepatocellular carcinoma. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/42919977 | PubMed |
| 42524197 | A Prognostic Risk Model for Hepatocellular Carcinoma Integrating Ferroptosis and Metabolic Reprogramming Signatures. | J Cancer | 2026 | https://conductscience.org/library/papers/42524197 | PubMed |
| 42310288 | Targeting STAT3-mediated lipid metabolism reprogramming overcomes chemoresistance in acute myeloid leukemia. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42310288 | PubMed |
| 42292467 | Study of JCAD for prognosis and immune infiltration in hepatocellular carcinoma. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292467 | PubMed |
| 41943830 | Mechanistic Insights into the FOXM1/BUB1 axis-Mediated Oncogenic Signaling in Hepatocellular Carcinoma. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/41943830 | PubMed |
| 41815139 | Causal relationship between metabolic syndrome and gastric cancer: insights from comprehensive analysis and biomarker identification. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/41815139 | PubMed |
| 41417218 | Deciphering the mechanism of aristolochic acid I-driven hepatocellular carcinoma through integrated network toxicology and bioinformatics. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/41417218 | PubMed |
| 41099846 | Integrated bioinformatics and molecular docking ıdentify CCNB1, CDK1, and CYP1A2 as therapeutic targets of phytochemicals in hepatocellular carcinoma. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/41099846 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CCNB1 | 891 | PubTator's text mining | https://conductscience.org/library/genes/891 | NCBI Gene |
| FOXM1 | 2305 | PubTator's text mining | https://conductscience.org/library/genes/2305 | NCBI Gene |
| SNRPB | 6628 | PubTator's text mining | https://conductscience.org/library/genes/6628 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40682115
GET https://conductscience.org/api/papers/v1/40682115/references?page=2